- Home
- AIP vs SVRA Comparison
AIP vs SVRA Comparison
Compare AIP & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIP
- SVRA
- Stock Information
- Founded
- AIP 2003
- SVRA 2007
- Country
- AIP United States
- SVRA United States
- Employees
- AIP N/A
- SVRA N/A
- Industry
- AIP Semiconductors
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- AIP Technology
- SVRA Health Care
- Exchange
- AIP Nasdaq
- SVRA Nasdaq
- Market Cap
- AIP 579.6M
- SVRA 527.2M
- IPO Year
- AIP 2021
- SVRA N/A
- Fundamental
- Price
- AIP $14.33
- SVRA $3.95
- Analyst Decision
- AIP Strong Buy
- SVRA Buy
- Analyst Count
- AIP 5
- SVRA 8
- Target Price
- AIP $16.30
- SVRA $6.88
- AVG Volume (30 Days)
- AIP 726.4K
- SVRA 1.7M
- Earning Date
- AIP 11-04-2025
- SVRA 11-13-2025
- Dividend Yield
- AIP N/A
- SVRA N/A
- EPS Growth
- AIP N/A
- SVRA N/A
- EPS
- AIP N/A
- SVRA N/A
- Revenue
- AIP $65,931,000.00
- SVRA N/A
- Revenue This Year
- AIP $19.05
- SVRA N/A
- Revenue Next Year
- AIP $17.57
- SVRA N/A
- P/E Ratio
- AIP N/A
- SVRA N/A
- Revenue Growth
- AIP 20.45
- SVRA N/A
- 52 Week Low
- AIP $5.46
- SVRA $1.89
- 52 Week High
- AIP $15.92
- SVRA $4.51
- Technical
- Relative Strength Index (RSI)
- AIP 56.19
- SVRA 50.44
- Support Level
- AIP $12.24
- SVRA $4.14
- Resistance Level
- AIP $15.92
- SVRA $4.51
- Average True Range (ATR)
- AIP 1.00
- SVRA 0.22
- MACD
- AIP -0.03
- SVRA -0.05
- Stochastic Oscillator
- AIP 55.77
- SVRA 11.63
About AIP Arteris Inc.
Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum profit from Asia Pacific.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.